Prognostic Value of Soluble Urokinase Plasminogen Activation Receptor (SUPAR) to Rule Out Complications in Patients Admitted in Emergency Department for Acute Abdominal Pain.
Clinical trial NCT05580016 · COMPLETED
Trial details
- NCT number
- NCT05580016
- Sponsor
- Poitiers University Hospital
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2023-01-09
- Primary completion
- 2023-11-27
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.